Protein– tag –
-
Kymera Therapeutics Initiates Phase 1 Clinical Trial for Oral STAT3 Degrader KT-XXX
Kymera Therapeutics Press Release USA Overview Kymera Therapeutics has announced the initiation of a Phase 1 clinical trial for its lead STAT3 degrader candidate, KT-XXX. The study aims to evaluate the safety, pharmacokinetics (PK), and ... -
Arvinas Secures IND Clearance for Oral LRRK2 Degrader ARV-102, Expanding Neurodegenerative Pipeline and Partnering with Michael J. Fox Foundation
Arvinas Press Release / MarketBeat / GLOBE NEWSWIRE USA Overview Arvinas announced FDA approval of its Investigational New Drug (IND) application for ARV-102, an oral PROTAC protein degrader designed for specific neurodegenerative diseas... -
AlphaFold-Derived Optimized Protein Demonstrates Significant Efficacy in Autoimmune Disease Animal Models, Accelerating AI-Driven Protein Therapeutic Design
bioRxiv Unknown Overview A bioRxiv preprint details preclinical development of a novel therapeutic protein with structure predicted and optimized using AlphaFold. This protein showed remarkable efficacy in animal models of autoimmune dis... -
Modular Input-Output Biosensor Design Using De Novo Protein Switches Enables Colorimetric Detection of GLP-1, NPY, PYY at Clinically Relevant Levels
ACS Sensors (ACS Publications) Unknown Overview A modular input-output biosensor design employing de novo protein switches has been introduced, successfully developing functional biosensors responsive to helical binders like GLP-1, NPY, ... -
Top 20 Biomanufacturing and CDMO Providers for 2026: Driving Innovation in Biopharma Production
Healthcare Ranking USA Overview The 2026 ranking of top biomanufacturing and Contract Development and Manufacturing Organization (CDMO) providers highlights industry leaders such as Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fi... -
Germany Commits to Food Tech Innovation Hub by 2027, Aiming to Accelerate Precision Fermentation and Cultivated Food Commercialization
Foovo -フードテックニュースの専門メディア- Japan Overview The German government has designated precision fermentation and cell-cultured foods as strategic priorities for building a resilient agricultural and food system. It plans to esta... -
Regulatory & Policy Shifts Reshape Global Biologics Manufacturing Strategy: Focus on EU Reform, UK Decentralization, and US Tariffs
IMAPAC UK Overview Regulatory and policy shifts, including EU Pharma Reform, UK decentralized manufacturing initiatives, and U.S. tariffs, are fundamentally reshaping global biologics manufacturing strategies. Notably, the UK has establi... -
WuXi Biologics Intensifies Focus on South Korea to Bolster K-Biotech Partnerships Amid US Pressure
BioCentury (Chosun Biz) South Korea Overview WuXi Biologics is expanding its sales efforts in South Korea, actively targeting K-biotech companies amidst increasing U.S. legislative scrutiny on Chinese biotech firms. As a major global Con... -
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a... -
Platelet Membrane-Coated Nanoparticles: Bioengineered Carriers for Enhanced Targeted Drug Delivery
AIP Publishing USA Overview Platelet membrane-coated nanoparticles (PM-NPs) are an innovative bioinspired coating strategy to enhance targeted drug delivery, offering improved immune evasion, prolonged circulation, and enhanced disease-h...
